Search

Search Constraints

You searched for: Author/Creator Giacomelli, Roberto

Search Results

1. 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19. Issue 1 (7th October 2021)

3. A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sjögren's syndrome. (19th September 2020)

4. A3.1 Pathogenic role of IL-17 producing double negative (DN) T cells in primary sjögren's syndrome. (31st January 2014)

5. A3.8 Association between clinical, histopathological and molecular features in primary Sjögren's Syndrome: a retrospective study. (31st January 2014)

6. AB0458 A PHASE II RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF OF CONCEPT STUDY OF ORAL SELETALISIB IN PATIENTS WITH PRIMARY SJÖGREN'S SYNDROME (PSS). (June 2019)

7. AB0550 PHENOTYPE OF BIOPSY-PROVEN PATIENTS WITH PRIMARY SJÖGREN SYNDROME LACKING RO AUTOANTIBODIES: HIGH FREQUENCY OF DRYNESS SYMPTOMS WITH LOW SYSTEMIC ACTIVITY (BIG DATA SJÖGREN PROJECT). (June 2019)

8. Absent or suboptimal response to booster dose of COVID-19 vaccine in patients with autoimmune systemic diseases. Issue 131 (July 2022)

9. Adipocytokines in Rheumatoid Arthritis: The Hidden Link between Inflammation and Cardiometabolic Comorbidities. (21st November 2018)